our Commitment to Lead

The founder and CEO of Asklepian Consulting, Dr Nafees Malik, is a published thought leader in the commercialisation of pharmaceutical and advanced therapies, with publications in many of the world's most prestigious scientific journals, including Nature, Nature Biotechnology, Nature Reviews Clinical Oncology and Lancet.

For further information on any of these publications, please contact us on: thoughtleadership@asklepianconsulting.com

Book Chapters

  1. Malik NN, Durdy MB. Cell Therapy Landscape: Autologous and Allogeneic Approaches. In: Atala A, Allickson JG (Eds.) Translational Regenerative Medicine. Elsevier Academic Press; 2015. p.87-106

  2. Malik NN, Allsopp TE, Smith DM. Strategic Alliances, Mergers and Acquisitions in Regenerative Medicine. In: Vertès AA et al. (Eds.) Stem Cells in Regenerative Medicine: Science, Regulation, and Business Strategies. Wiley-Blackwell; 2015. p.643-664

Journal Papers

  1. Malik NN, Durdy MB. Commercialisation of CAR T-cell therapies: business model spectrum. Drug Discovery Today (2017), 22, 1-4

  2. Malik NN, Durdy MB. CAR T-cell therapies: formulation–product–proposition framework for commercialisation. Drug Discovery Today (2016), 21, 1731–1734

  3. Malik NN, Durdy MB. Customer pyramid framework for CAR T-cell therapies in immuno-oncology. Drug Discovery Today (2016), 21, 1563–1565

  4. Malik NN. Pay-for-performance pricing for a breakthrough heart drug: learnings for cell and gene therapies. Regenerative Medicine 2016;11(3):225-227

  5. Malik NN. Reimbursement and adoption of advanced therapies: the 5-C framework. Regenerative Medicine 2014;9(5):573-578

  6. Malik NN. Allogeneic versus autologous stem cell therapy: a comparison of manufacturing costs and commercialization challenges. BioPharm International 2012;25(7):36-40

  7. Malik NN. Personalized drugs should cut care costs. Nature 2012;485:582

  8. Malik NN. Overhauling the reimbursement system for molecular diagnostics. Nature Biotechnology 2011;29:390-391

  9. Malik NN. Controlling the cost of innovative cancer therapeutics. Nature Reviews Clinical Oncology 2009;6:550-552

  10. Malik NN. Over-the-counter statins: a bad decision for public health. Lancet 2004;364:411

  11. Malik NN, Khan Y. Personalized medicine: potential impact on the biopharmaceutical industry. Drug Discovery Today 2010;15:881-883

  12. Malik NN. Biotech acquisitions by big pharma. Drug Discovery Today 2009;14:818-821

  13. Malik NN. Drug discovery: past, present and future. Drug Discovery Today 2008;13:909-912

  14. Malik NN. Controlling healthcare spending through personalised medicine. Pharma 2013 Jan-Feb:32-34

  15. Malik NN. Is the future of big pharma biotech? Drug Discovery 2009;6:14-16

  16. Malik NN. Key issues in the pharmaceutical industry: consequences on R&D. Expert Opinion on Drug Discovery 2009;4:15-19

  17. Malik NN. Pharma-biotech partnerships: lessons for personalized medicine. Pharmaceutical Technology 2009;33:113-114

  18. Malik NN. Has the era of blockbuster drugs come to an end? BioPharm International 2007;20(12):114

  19. Malik NN. Integration of diagnostic and communication technologies. Journal of Telemedicine and Telecare 2009;15:323-326

Newspaper Articles

  1. Malik NN. Strict rules threaten release of new drugs. Wall Street Journal 06/02/2007
  2. Malik NN. Vioxx scandal runs the risk of stifling pioneering drug research. Financial Times 11/03/2006